<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04687878</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SBMU.PHNS.REC.1398.094</org_study_id>
    <nct_id>NCT04687878</nct_id>
  </id_info>
  <brief_title>The Effect of Intranasal Insulin on Motor and Non-motor Symptoms in Parkinson's Disease Patients</brief_title>
  <official_title>Evaluating the Effect of Intranasal Insulin Administration on Motor and Non-motor Symptoms in Parkinson's Disease Patients; a Randomized Double-blinded Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>dr.dargahi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of intranasal insulin on motor and non-motor symptoms of&#xD;
      patients with Parkinson's disease over a 12-week period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a single-center, parallel and double-blind study. Patients with Parkinson's&#xD;
      disease referred to Movement Clinic of Shohada-e-Tajrish Hospital will randomly receive&#xD;
      intranasal placebo or insulin, every day, twice a day for 12 weeks. Motor and non-motor&#xD;
      symptoms will be evaluated in four time points; baseline, 4, 8 and 12 weeks after treatments.&#xD;
      Primary outcome is motor symptoms (MDS-UPDRS; part III, IV), and secondary outcomes are motor&#xD;
      (gait balance) and non-motor (MDS-UPDRS part I, II, cognition, depression, anxiety and&#xD;
      fatigue) symptoms. Patients, researchers (physicians, outcome assessors) and data analysts&#xD;
      are blinded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III, IV</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III, IV assess the motor signs of Parkinson's Disease; higher score means more severity of the motor symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I, II</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part I, II assess the non motor signs of PD; higher score means more severity of the symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease severity</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>The modified Hoehn and Yahr Scale (HY) is used to assess severity of Parkinson's Disease. The scale ranges from 1 to 5. The lower score indicates better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Falling</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Tinetti Balance Assessment Tool indicates the risk of falling, higher scores is indicative of low risk for falling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive score</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>The Montreal Cognitive Assessment (MoCA) scores range between 0 and 30 with higher scores indicative of better cognitive performance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression score</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Beck's Depression Inventory II (BDI-II) scores range between 0 and 63; higher scores is indicative of more severe depression.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety score</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Beck Anxiety Inventory (BAI) scores range between 0 and 63; higher scores is indicative of more anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue score</measure>
    <time_frame>Base line, 4, 8 and 12 weeks after intervention</time_frame>
    <description>Fatigue Severity Scale (FSS) scores range between 0 and 7; higher scores is indicative of severe fatigue.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regular Insulin, 20 IU twice a day, intranasally, every day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline, twice a day, intranasally, every day for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin</intervention_name>
    <description>20 IU twice a day, intranasally, every day for 12 weeks</description>
    <arm_group_label>Insulin</arm_group_label>
    <other_name>Insulin regular</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>twice a day, intranasally, every day for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man and woman over 17 years old&#xD;
&#xD;
          -  Patient with Parkinson's disease according to UK Parkinson's Disease Society Brain&#xD;
             Bank Diagnostic Criteria&#xD;
&#xD;
          -  Provide written informed consent to participate in the study.&#xD;
&#xD;
          -  Understand that they may withdraw their consent at any time.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Patients with diabetes and taking anti-hyperglycemic drugs&#xD;
&#xD;
          -  Patients with other neurodegenerative diseases like multiple system atrophy,&#xD;
             Huntington's, Wilson's disease, Alzheimer's, Amyotrophic lateral sclerosis (ALS),&#xD;
             progressive supranuclear palsy, etc.&#xD;
&#xD;
          -  Patients who cannot walk for more than one minute without help&#xD;
&#xD;
          -  A history of allergic reaction to insulin&#xD;
&#xD;
          -  The presence of inflammation of nasal cavity that may prevents absorption of insulin&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Leila Dargahi, PharmD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mehri Salari, MDFellowship</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abolhassan Ahmadiani, PharmD/PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Neda Valian, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leila Mohaghegh Shalmani, PharmD/PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Helia Ashourizadeh, Intern</last_name>
    <role>Study Chair</role>
    <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leila Dargahi, PharmD/PhD</last_name>
    <phone>+989125069930</phone>
    <email>l.dargahi@sbmu.ac.ir</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shahid Beheshti University of Medical Sciences, Shohada-e-Tajrish Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mehri Salari, MDFelloship</last_name>
      <phone>+989124972186</phone>
      <email>mehri.salari@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 29, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shahid Beheshti University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>dr.dargahi</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>Insulin</keyword>
  <keyword>Intranasal</keyword>
  <keyword>Motor symptoms</keyword>
  <keyword>Non-motor symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

